RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: H3
Target: Hirame rhabdovirus (HIRRV)
Type of nucleic acid: ssRNA
Sequence: 5'GUCCUAUACAGUGUGACCGGUUGAAAGUGGGUUCGUUG3'
Sequence length: 38
GC content: 0.5
Affinity: Not reported
Pool type: 5′‐GGGCCAGGCAGCGAG-N40‐CCGACCACACGCGTCCGAGA‐3′
Pool random region: 40
Binding buffer/conditions: 2.5 mm MgCl2, 100 mm NaCl, 20 mm Tris–HCl, pH 7.5
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Here, we describe four Hirame rhabdovirus (HIRRV)-RNA aptamers (H1, H2, H3 and H4) that we obtained from an in vitro process called the systematic evolution of ligands by exponential enrichment (SELEX). The HIRRV-RNA aptamers specifically bind to HIRRV. Thus, the recombinant R. sulfidophilum might be a powerful tool for the prevention of HIRRV in aquaculture."
Reference (2012, J Fish Dis ): Hwang, S. D., Midorikawa, N., Punnarak, P., Kikuchi, Y., Kondo, H., Hirono, I., & Aoki, T. (2012). Inhibition of Hirame rhabdovirus growth by RNA aptamers. Journal of fish diseases, 35(12), 927–934. https://doi.org/10.1111/jfd.12000
Aptamer: CSC-35
Target: Colorectal cancer stem cells (CR-CSC)
Type of nucleic acid: ssDNA
Sequence: 5'GGCAGGAAGACAAACATGAGGCGGTAAGATCCTGGAGTTCTGTGTGTGCGGCTGTTGGGTCTGTGGTGCTGT3'
Sequence length: 72
GC content: 0.5555555555555556
Affinity: Kd: 44.8 ± 10.2 nM
Pool type: 5'-GGCAGGAAGACAAACA-N40-GGTCTGTGGTGCTGT-3'
Pool random region: 40
Binding buffer/conditions: 1 L of Dulbecco's phosphate-buffered saline (DPBS, Invitrogen Co., USA), 100 mg transfer ribonucleic acid (Sigma Co., USA), 4.5 g of glucose, and 5 mL of 1 M MgCl2
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Colorectal cancer (CRC) is the most frequently diagnosed cancer around the world, causing about 700,000 deaths every year. These results demonstrated that the integrated microfluidic system is able to rapidly screen aptamers with high affinity and selectivity within a shorter period of time. This technology is promising for screening of aptamer targeting agents for these cancer cells, which could be useful for early diagnosis of CR-CSC/CRC or even target therapeutics."
Reference (2015, Sci Rep ): Hung, L. Y., Wang, C. H., Che, Y. J., Fu, C. Y., Chang, H. Y., Wang, K., & Lee, G. B. (2015). Screening of aptamers specific to colorectal cancer cells and stem cells by utilizing On-chip Cell-SELEX. Scientific reports, 5, 10326. https://doi.org/10.1038/srep10326
Aptamer: HCT-17
Target: Colon carcinoma cell lines (HCT-8), Human
Type of nucleic acid: ssDNA
Sequence: 5'GGCAGGAAGACAAACATGGTTGTGTTTTTTTTTGTGTGGCTTCGTATGTTGTTGCGGGTCTGTGGTGCTGT3'
Sequence length: 71
GC content: 0.4647887323943662
Affinity: Kd: 28.5 ± 8.5 nM
Pool type: 5'-GGCAGGAAGACAAACA-N40-GGTCTGTGGTGCTGT-3'
Pool random region: 40
Binding buffer/conditions: 1 L of Dulbecco's phosphate-buffered saline (DPBS, Invitrogen Co., USA), 100 mg transfer ribonucleic acid (Sigma Co., USA), 4.5 g of glucose, and 5 mL of 1 M MgCl2
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Colorectal cancer (CRC) is the most frequently diagnosed cancer around the world, causing about 700,000 deaths every year. These results demonstrated that the integrated microfluidic system is able to rapidly screen aptamers with high affinity and selectivity within a shorter period of time. This technology is promising for screening of aptamer targeting agents for these cancer cells, which could be useful for early diagnosis of CR-CSC/CRC or even target therapeutics."
Reference (2015, Sci Rep ): Hung, L. Y., Wang, C. H., Che, Y. J., Fu, C. Y., Chang, H. Y., Wang, K., & Lee, G. B. (2015). Screening of aptamers specific to colorectal cancer cells and stem cells by utilizing On-chip Cell-SELEX. Scientific reports, 5, 10326. https://doi.org/10.1038/srep10326
Aptamer: ABA1–ABA65
Target: Angiopoietin-2 (Ang2), Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGCACAGAGGTCAGATGACTTGTAGGGTTCGGCTGGTCAGGGTGTCCAAGTCTGTGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGGGTGGTTGGGGGTTGTTGTTTTGGGGGTGGAGGGTCCTATGCGTGCTACCGTGAA3′
Sequence length: 145
GC content: 0.4689655172413793
Affinity: Kd: 0.062 nM
Pool type: 5′-AGCAGCACAGAGGTCAGATG-40N-CCTATGCGTGCTACCGTGAA-3′
Pool random region: 40
Binding buffer/conditions: 20 mM HEPES, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.4
Divalent salt: MgCl/CaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: N/a
Post-SELEX modifications: Linked aba1 with aba65 through a flexible, poly-t linker
Application as quoted in the referenced paper: Research and Detection: " Affinity reagent pairs that recognize distinct epitopes on a target protein can greatly improve the sensitivity and specificity of molecular detection. nfortunately, aptamer pairs are difficult to generate, primarily because conventional selection methods preferentially yield aptamers that recognize a dominant "hot spot" epitope. Our array-based discovery platform for multivalent aptamers (AD-MAP) overcomes this problem to achieve efficient discovery of aptamer pairs. As a proof of concept, we have used AD-MAP to discover novel DNA aptamer pairs that bind to human angiopoeitin-2 (Ang2), an important protein mediator of angiogenesis for colon, prostate and breast cancers"
Reference (2015, Anal Chem ): Cho, M., Oh, S. S., Nie, J., Stewart, R., Radeke, M. J., Eisenstein, M., Coffey, P. J., Thomson, J. A., & Soh, H. T. (2015). Array-based discovery of aptamer pairs. Analytical chemistry, 87(1), 821–828. https://doi.org/10.1021/ac504076k
Aptamer: TC-6
Target: Papillary thyroid carcinoma cell line TPC-1
Type of nucleic acid: ssDNA
Sequence: 5′ATCCATTGCCACTGACTACCTACCACCACACCACATCTCCAGCCTCAACGTCGCTTTGTCGAAGTCAGTCGGTCGTTAGT3′
Sequence length: 80
GC content: 0.525
Affinity: Kd: 57.66 ± 5.93 nM
Pool type: 5′-ATCCATTGCCACTGACTACC-N40-GAAGTCAGTCGGTCGTTAGT-3′
Pool random region: 40
Binding buffer/conditions: 5 mmol/L MgCl2 and 4.5 g/L glucose in Dulbecco's phosphate-buffered saline, 0.1 mg/mL yeast tRNA and 1 mg/L bovine serum albumin (BSA)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " TC-6 is a potential candidate for developing novel tools for diagnosis and targeted therapy of PTC. The truncated aptamer TC-6d could maintain its binding capability and recognize PTC in a manner similar to that of full-length aptamer. Our results demonstrated that TC-6 had high affinity to PTC in cell lines, tissue slides and tumor-bearing mice. Therefore, TC-6 shows promise in the diagnosis of thyroid malignant diseases and targeted therapy of PTC."
Reference (2019, Anal Chem ): Zhong, W., Pu, Y., Tan, W., Liu, J., Liao, J., Liu, B., Chen, K., Yu, B., Hu, Y., Deng, Y., Zhang, J., & Liu, H. (2019). Identification and Application of an Aptamer Targeting Papillary Thyroid Carcinoma Using Tissue-SELEX. Analytical chemistry, 91(13), 8289–8297. https://doi.org/10.1021/acs.analchem.9b01000
Aptamer: Apt122
Target: Tacrolimus (TAC)
Type of nucleic acid: ssDNA
Sequence: 5'GCTGTGTGACTCCTGCAAACTACTGGTGTTCCTTGCCCTGTTTCAATAAATCGTGTGTGCCGCAGCTGTATCTTGTCTCC3'
Sequence length: 80
GC content: 0.5
Affinity: Kd: 56.45 nM
Pool type: 5´-GCTGTGTGACTCCTGCAA-N43-GCAGCTGTATCTTGTCTCC-3´
Pool random region: 43
Binding buffer/conditions: Binding buffer (20 mM Tris−HCl, 100 mM NaCl, 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2 and 0.02% Tween 20, pH 7.6)
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Tacrolimus (TAC) is an immunosuppressant for preventing solid-organ transplant rejection. Because of its narrow therapeutic window, analytical methods which can detect TAC in serum samples with high accuracy and reliability are required. In this study, specific aptamers (Apt122 and Apt125) for TAC were isolated via systematic evolution of ligands by exponential enrichment method using magnetic beads to immobilize the target. The designed aptasensor could detect TAC in phosphate buffer saline"
Additional information: Fluorescence is observed when Apt122 is labled with ATTO 647 N; allows for TAC detection
Reference (2020, J Pharm Biomed Anal ): Mansouri, A., Abnous, K., Nabavinia, M. S., Ramezani, M., & Taghdisi, S. M. (2020). In vitro selection of tacrolimus binding aptamer by systematic evolution of ligands by exponential enrichment method for the development of a fluorescent aptasensor for sensitive detection of tacrolimus. Journal of Pharmaceutical and Biomedical Analysis, 177, 112853. https://doi.org/10.1016/j.jpba.2019.112852
Aptamer: Apt125
Target: Tacrolimus (TAC)
Type of nucleic acid: ssDNA
Sequence: 5'GCTGTGTGACTCCTGCAAACTACTGGTGTTCCTTGCCCTGTTTCAATAAATCGTGTGTGCCGCAGCTGTATCTTGTCTCC3'
Sequence length: 80
GC content: 0.5
Affinity: Kd: 180 nM
Pool type: 5´-GCTGTGTGACTCCTGCAA-N43-GCAGCTGTATCTTGTCTCC-3´
Pool random region: 43
Binding buffer/conditions: Binding buffer (20 mM Tris−HCl, 100 mM NaCl, 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2 and 0.02% Tween 20, pH 7.6)
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " Tacrolimus (TAC) is an immunosuppressant for preventing solid-organ transplant rejection. Because of its narrow therapeutic window, analytical methods which can detect TAC in serum samples with high accuracy and reliability are required. In this study, specific aptamers (Apt122 and Apt125) for TAC were isolated via systematic evolution of ligands by exponential enrichment method using magnetic beads to immobilize the target. The designed aptasensor could detect TAC in phosphate buffer saline"
Reference (2020, J Pharm Biomed Anal ): Mansouri, A., Abnous, K., Nabavinia, M. S., Ramezani, M., & Taghdisi, S. M. (2020). In vitro selection of tacrolimus binding aptamer by systematic evolution of ligands by exponential enrichment method for the development of a fluorescent aptasensor for sensitive detection of tacrolimus. Journal of Pharmaceutical and Biomedical Analysis, 177, 112853. https://doi.org/10.1016/j.jpba.2019.112852
Aptamer: 13
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUCCUGGCUCGUACGCAAGUACUAGAGACACAG3'
Sequence length: 38
GC content: 0.5
Affinity: Kd: 3.6*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 75
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUUGGACUCCGUACGCAAGUACGUCGAGAUACAG3'
Sequence length: 39
GC content: 0.4871794871794871
Affinity: Kd: 1.9*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: 53
Target: Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE))
Type of nucleic acid: ssRNA
Sequence: 5'AUUCUGUUUGGAGGUACGCAAGUACGCGCUCACAG3'
Sequence length: 35
GC content: 0.5142857142857142
Affinity: Kd: 2.0*
Pool type: 5'-AUUCUGU-N6.9-GUACGCAAGUAC-N6.9-ACAG-3'
Pool random region: 15
Binding buffer/conditions: 50 mM KCl, 50 mM Tris-Cl, pH 8.0
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " A population of improved Rev-binding aptamers can be used to inhibit viral
replication, as opposed to a single RNA species. In contrast to other pharmaceuticals, this approach will make it extremely difficult for HIV-1 to accumulate mutations that can simultaneously evade a multitude of different RRE decays."
Additional information: *Activity values are described as "representing relative Kd's" with no units

6.9 means Both random sequence tracts were systematically varied from 6 to 9 nts in length.

Sequences at the defined 5' and 3' ends of the 79.9
pool are, respectively, 5'-GGTAATACGACTCACTATAGGG_x0002_AACTCG4TG4AGCGAATT-3' and 5'-GCCTATCTATCGGAT_x0002_CCACG-3'.
Reference (1993, Nucleic Acids Res ): Giver, L., Bartel, D., Zapp, M., Pawul, A., Green, M., & Ellington, A. D. (1993). Selective optimization of the Rev-binding element of HIV-1. Nucleic acids research, 21(23), 5509–5516. https://doi.org/10.1093/nar/21.23.5509
Aptamer: W13 (clone 8)
Target: Tobramycin
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAAUUCCGACCAGAAGCUUCGUUUGGGGUCCCACAACACAGGUCUUUGCUGGUCAUAUAUGCGUGUCCUCUAGGAAGUGCAUAUGUGCGUCUACAUGGAUCCUCA3'
Sequence length: 109
GC content: 0.5045871559633027
Affinity: Kd: 4.3 ± 0.7 µM
Pool type: 5'-GGGAGAAUUCCGACCAGAAGCUU-N60-CAUAUGUGCGUCUACAUGGAUCCUCA-3'
Pool random region: 60
Binding buffer/conditions: 140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 20 mM Tris acetate at pH 7.4
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic, Detection, and Research: " When coupled with the use of high-resolution NMR and X-ray spectroscopic studies, it ought to be possible to define the specific ways in which RNA molecules recognize aminoglycoside antibiotics.This information will be important in the design of novel molecules that will bind to and interfere with the function of specific RNA structures. Molecules of this type could be useful as paradigms for the design of novel drugs."
Reference (1995, Chem Biol ): Wang, Y., & Rando, R. R. (1995). Specific binding of aminoglycoside antibiotics to RNA. Chemistry & biology, 2(5), 281–290. https://doi.org/10.1016/1074-5521(95)90047-0
Aptamer: G
Target: Rous sarcoma virus (RSV)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGCUCAGAAUAAACGCUCAAUAAUGUUGGACCUAGUGGAGGGUGUGUGGAGGGAUUGGUUCGACAUGAGGCCCGGAUCCGGC3'
Sequence length: 85
GC content: 0.5529411764705883
Affinity: Not reported
Pool type: 5'-GCCGGATCCGGGCCTCATGTCGAA-N40-TTGAGCGTTTATTCTGAGCTCCC-3'
Pool random region: 40
Binding buffer/conditions: 2.5 mM MgCl2/100 mM NaCl/20 mM Tris HCl, pH 7.5
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " The selection of the anti-RSV RNA and RNA analogs by intact virions immediately suggests the potential application of this approach to develop RNA and RNA analogs as inhibitors of other viruses such as human immunodeficiency virus. Aptamers change the structures of viral surface proteins so that these proteins can no longer function in steps critical for viral infection, such as viral attachment and virus-cell membrane fusion. Alternatively, some of the structural changes may trigger pathways to inhibit the steps which normally occur after virus internalization, such as the uncoating and the expression of the virus genome."
Additional information: 2'F-RNA: 2'-F-CTP and 2'-F-UTP replaced CTP and UTP. Transcribed a pool of 2'-F-RNA from unmodified RNA after 9 cycles of selection by RSV
Reference (1995, Proc Natl Acad Sci U S A ): Pan, W., Craven, R. C., Qiu, Q., Wilson, C. B., Wills, J. W., Golovine, S., & Wang, J. F. (1995). Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proceedings of the National Academy of Sciences of the United States of America, 92(25), 11509–11513. https://doi.org/10.1073/pnas.92.25.11509
Aptamer: H
Target: Rous sarcoma virus (RSV)
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5'GGGAGCUCAGAAUAAACGCUCAAUGUUAGGACCCUCGAGGGAGGUUGCGCAGGGUGGGGAGGGUUCGACAUGAGGCCCGGAUCCGGC3'
Sequence length: 87
GC content: 0.6206896551724138
Affinity: Kd: ~2-3 μg of viral protein per ml)
Pool type: 5'-GCCGGATCCGGGCCTCATGTCGAA-N40-TTGAGCGTTTATTCTGAGCTCCC-3'
Pool random region: 40
Binding buffer/conditions: 2.5 mM MgCl2/100 mM NaCl/20 mM Tris HCl, pH 7.5
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " The selection of the anti-RSV RNA and RNA analogs by intact virions immediately suggests the potential application of this approach to develop RNA and RNA analogs as inhibitors of other viruses such as human immunodeficiency virus. Aptamers change the structures of viral surface proteins so that these proteins can no longer function in steps critical for viral infection, such as viral attachment and virus-cell membrane fusion. Alternatively, some of the structural changes may trigger pathways to inhibit the steps which normally occur after virus internalization, such as the uncoating and the expression of the virus genome."
Additional information: 2'F-RNA: 2'-F-CTP and 2'-F-UTP replaced CTP and UTP. Transcribed a pool of 2'-F-RNA from unmodified RNA after 9 cycles of selection by RSV
Reference (1995, Proc Natl Acad Sci U S A ): Pan, W., Craven, R. C., Qiu, Q., Wilson, C. B., Wills, J. W., Golovine, S., & Wang, J. F. (1995). Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proceedings of the National Academy of Sciences of the United States of America, 92(25), 11509–11513. https://doi.org/10.1073/pnas.92.25.11509
Aptamer: C5
Target: Human immunodeficiency virus type 1 Rev (HIV-1 Rev)
Type of nucleic acid: ssRNA
Sequence: 5'GGGAGAUACCAGCUUAUUCAAUUCAAGAAGUGGAAAUGCGCAGCGACCAUGAAACCUCGCAUGGUUCAUCGAUUGUUUGGAUAGUGUCUGUGUGAGAUAGUAAGUGCAAUCU3'
Sequence length: 112
GC content: 0.4375
Affinity: Kd: 19-36 nM
Pool type: 5'-GGGAGAUACCAGCUUAUUCAAUU-N71-AGAUAGUAAGUGCAAUCU-3'
Pool random region: 71
Binding buffer/conditions: 500 ul of 10 mM Hepes, pH 7.4/100 mM NaCl
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: "RNA aptamers were selected to bind to the isolated Rev34_50 peptide. These results suggest that artificially selected binding cusps may have much in common with those found on natural molecules and have important implications for the development of novel diagnostic reagents and strategies for intracellular immunization"
Additional information: Pool was not stated, but I figured it out using the figures
Reference (1996, Proc Natl Acad Sci U S A ): Xu, W., & Ellington, A. D. (1996). Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope. Proceedings of the National Academy of Sciences of the United States of America, 93(15), 7475–7480. https://doi.org/10.1073/pnas.93.15.7475
Aptamer: V2 Hammerhead Ribozyme
Target: Adenosine triphosphate (ATP)

Type of nucleic acid: ssRNA
Sequence: 5'UUUGUAGGCGACCUACCACUCUCGUGGCCCAGUGCAUUGCUGCGACCGAAGUCGCCAGUUUCUUCCCAAAUGUCGUCGCCAUCUCUUCC3'
Sequence length: 89
GC content: 0.5617977528089888
Affinity: Not reported
Pool type: 5'-TTTGTAGGCGACCTACCACTCTCGTGG-N5-TTGCTGCGACCGAAGTCGCCAGTTTCTTCCCAA-N9-GTCGCCATCTCTTCC-3'
Pool random region: 14
Binding buffer/conditions: 50 mM Tris-HCl, pH 7.5, at 23 °C, and 20 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: Not reported
Application as quoted in the referenced paper: Detection: " This finding, taken together with other reports of the in vitro selection of unique self-cleaving ribozymes, suggests that many novel ribozymes with simmilar catalytic activities have yet to be found. The application of in vitro selection using an unbiased starting pool of random sequence of RNA is likely to produce novel self-cleaving ribozymes with catalytic rates that meet or perhaps even exceed those of natural ribozymes"
Additional information: * The reported pool in the material section stated N5 and then N9, while figure 6 stated the order of the random region to be N9 and then N5. The sequence of V2 Trans which used to access the catalutic activity is 5'GCCGUAGGUUGCCC3'
DNA library/pool was used as a template to generate the RNA pool used in the selection. A T7 promoter sequence might be necessary to use this DNA library/pool as a template to generate the RNA pool in the selection.
Reference (1997, RNA ): Tang, J., & Breaker, R. R. (1997). Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection. RNA (New York, N.Y.), 3(8), 914–925.